India will cap trade margins on non-scheduled cancer medicines at 30 percent of the maximum retail price, in a move aimed at easing the cost of treatment for patients. The National Pharmaceutical Pricing Authority, known as the NPPA, has issued an updated list covering 543 brands. The revised prices will take effect on 9 November 2026.
The NPPA said the list was compiled using data provided by pharmaceutical manufacturers as of 27 October. The change applies to medicines that are not already covered by scheduled price controls. For those products, the margin allowed between the price at which a seller buys a drug and the price printed on the pack will now be limited.
Trade margins matter because they form part of what a patient finally pays at a pharmacy counter. When the margin is high, the gap between the cost to the seller and the retail price can be wide. A cap sets a ceiling on that gap. The government has presented the step as a way to reduce the financial strain on households facing long treatment courses, where several medicines may be needed over weeks or months.
What the cancer price cap changes
Under the revised list, several cancer medicines show large reductions from their earlier printed prices. The price of an injection sold under the brand name BEVACIZAB has been lowered from Rs 21,767.70 to Rs 5,930.13.
The price of Debrumab 60 mg injection has decreased from Rs 22,031.25 to Rs 5,941. The two examples show how the margin cap can change the retail price of individual cancer medicines by a large amount, even though the size of the change will differ from brand to brand. Patients will pay the revised maximum retail price printed on each product once the new list takes effect.
The NPPA announced a rationalisation of trade margins for 137 non-scheduled cancer medicines on 17 October. Manufacturers were then instructed to submit their updated prices. The list of 543 brands now published is the result of that exercise. It covers more brands than the 137 medicines named in the October announcement, because a single medicine can be sold under several brand names and in different strengths or pack sizes.
How the revised cancer drug list was prepared
Price control in India works in two broad ways. Scheduled medicines, which are listed under the national list of essential medicines, have their ceiling prices fixed directly. Non-scheduled medicines are not subject to that same ceiling. For those products, the authorities have used trade margin rationalisation as a tool to limit how much can be added on top of the price at which a product changes hands in the supply chain.
In this case, the NPPA asked manufacturers to submit revised prices in line with the 30 percent cap. The authority then compiled those submissions into a single updated list. The list gives patients, pharmacists and hospitals a reference point for the new maximum retail prices for cancer medicines. A seller cannot charge more than the printed maximum for a listed brand, and the revised figure replaces the earlier price from 9 November.
The NPPA also indicated that the list will be updated whenever manufacturers submit further revised pricing information. Patients and pharmacists will therefore need to check the latest list, rather than rely on an older printed price.
What patients and pharmacies should check from 9 November
For patients, the practical change is straightforward. From 9 November, the maximum retail price for the 543 listed brands will be the revised figure. Anyone buying one of those cancer medicines should check the price printed on the pack and compare it with the price on the bill. If a bill shows a higher amount than the revised maximum, the patient can raise the matter with the seller and, if needed, with the pricing authority.
For pharmacies, the change means updating shelf prices for cancer medicines and billing systems to match the new list. Hospitals that dispense cancer medicines to inpatients will also need to apply the revised prices. The transition may take some care in the first days after 9 November, because stock bought earlier may still carry older printed prices. The published list, rather than an older label alone, is the guide to the price that should now apply.
The wider effect will depend on how fully the revised prices are applied across the country. A price list can only help patients if it is followed at the counter and if patients know about the change. From 9 November, the 543 brands on it will carry the lower maximum prices set out by the authority.